Oncology Launch: Vendor Stack Playbook for Commercial Teams

TL;DR

Oncology launches are not rare disease launches. The defining problem is split channel economics. IV biologics (checkpoint inhibitors, monoclonal antibodies, antibody-drug conjugates, bispecifics) flow through buy-and-bill on J-codes under the medical benefit, making providers the primary customer and dragging 340B, site-of-care steering, and white-bagging into every access conversation. Oral oncolytics (now 25 percent-plus of new approvals) run through specialty pharmacy under the pharmacy benefit, usually on limited distribution. CAR-T and cell therapies require certified treatment centers, apheresis chains, and product-specific safety infrastructure; FDA removed REMS for currently approved BCMA- and CD19-directed autologous CAR-T therapies in 2025. Buy-and-bill represents roughly 50 to 60 percent of specialty drug spending and dominates oncology economics. The vendor stack must cover both channels plus field reimbursement, real-world evidence, and medical affairs. Budget $10M to $25M of vendor spend in year one for a mid-size launch, before marketing. IRA Part B price negotiation and expanding white-bagging mandates are the two secular threats every launch plan should stress-test. For the rare disease counterpart, see Rare Disease Launch Playbook.

---

Why Oncology Launches Are Different

Four structural features distinguish oncology from every other therapy area.

1. Split channel economics. An oncology portfolio often spans IV biologics, oral oncolytics, and (for a handful of modalities) cell therapies. Each runs through a different reimbursement channel with different vendors, different PA workflows, and different patient financial flows.

2. Provider is the primary customer. For IV products, the oncologist practice or hospital outpatient department decides whether to stock the drug. Drug margin is 30 to 50 percent of community oncology practice economics. If a practice cannot get paid cleanly under buy-and-bill, it will not use the drug. This makes field reimbursement, J-code support, and coding education more important than DTC marketing.

3. Site-of-care and 340B politics. Hospital outpatient departments, community oncology practices, ambulatory infusion centers, and home infusion all compete for the same infusion. Payers push toward lower-cost settings. 340B entities pull toward hospital-based care. White-bagging mandates disrupt the traditional channel and create chain-of-custody exposure.

4. Clinical complexity. Immuno-oncology adverse events require multidisciplinary coordination. Biomarker testing gates eligibility for targeted therapies. Prior therapy failure documentation is standard. Appeals rates routinely exceed 30 percent. Clinical support is non-optional.

See Hub Services Buyer’s Guide for the general hub evaluation framework. This article layers oncology-specific requirements on top.

---

The Launch Phase Structure

Oncology launches map to four phases relative to PDUFA.

Phase 1: Strategic (T-18 and earlier). Define channel strategy (buy-and-bill vs SP vs both). Model 340B exposure and site-of-care mix. Scope REMS. Engage market access consulting for pricing, GTN, and payer research. Select RWE dataset. Make build-vs-buy decision on hub.

Phase 2: Access Infrastructure (T-12 to T-6). Hub services RFP and contracting. SP network design and LDD partner selection. Field reimbursement build (manager by T-12, FRMs by T-6). GPO contracting with McKesson, Cencora, and Cardinal Specialty. REMS stood up if required. Copay and PAP program design for both benefits.

Phase 3: Launch Readiness (T-6 to T-0). Hub go-live with mock claims and BV/PA testing. SP training and dispensing playbooks. FRM training on J-code, coding, billing, and appeals. KOL engagement and advisory boards. Disease-state and branded content live. PSP enrollment portals live.

Phase 4: Post-Launch (T-0 to T+18). Monitor time-to-first-dose, PA approval rate, and appeals win rate by payer. RWE flowing for HEOR and label expansion. FRM case volume analysis. Site-of-care expansion. Label expansion and lifecycle management planning.

---

Vendor Category × Oncology Archetype Matrix

The vendor stack depends on what you are launching. Three archetypes cover most of oncology.

Vendor Category	IV Biologic (Checkpoint / mAb / ADC)	Oral Oncolytic (Kinase inhibitor / Small mol)	CAR-T / Cell Therapy
Hub services	Required: medical-benefit BV, buy-and-bill support, FRM coordination	Required: pharmacy-benefit BV, copay, SP triage	Required: treatment center coordination, REMS, financial counseling
Specialty pharmacy	Optional (white-bagging fallback); required for SC variants	Required: LDD network of 3 to 10 SPs	Not applicable; CTC dispensing
Specialty distributor	Required: McKesson / Cencora / Cardinal Specialty	Not applicable	Manufacturer direct-to-CTC
Field reimbursement	Required: 10 to 30 FRMs depending on indication breadth	Helpful: 5 to 15 FRMs, often combined with market access	Specialized: 3 to 8 reimbursement specialists, CTC-facing
Infusion network	Required: optional ambulatory / home infusion for maintenance	Not applicable	Not applicable
REMS vendor	Product-specific	Less common	Product-specific; no longer required for current BCMA/CD19 autologous CAR-T
RWE / data	Required: Flatiron, ConcertAI, Tempus for HEOR and label expansion	Required: same datasets plus SP dispense data	Required: outcomes-based contracting infrastructure
KOL / medical affairs	Required: 15 to 40 US KOLs, tumor-specific	Required: same	Required: CTC-level relationships
Patient advocacy	Required: ACS, LLS, disease-specific foundations	Required	Required
Healthcare advertising / DTC	Common for broad tumor indications	Common for oral onc with patient-facing adherence	Rare; HCP-directed only

Cross-read: Rare Disease Launch Playbook for the contrasting single-channel, ultra-rare archetype.

---

Hub Services (Oncology-Specialized)

Oncology hub services are not generic hubs with an oncology label. The buy-and-bill component fundamentally changes the workflow. Oncology hubs must run medical-benefit investigation (payer medical policy lookups, site-of-care verification), buy-and-bill coding and billing support (J-code assignment, miscellaneous J-code guidance, medical-claim appeals), live FRM coordination for complex appeals and peer-to-peer, white-bagging handoff logistics, provider reimbursement education (ASP-plus-markup economics, 340B), and medical-benefit copay administration structured as reimbursement after treatment rather than POS adjudication.

Named oncology hub vendors:

• Cencora (Lash Group). Largest full-stack hub with oncology depth. Runs buy-and-bill programs for many top-20 oncology manufacturers. Dedicated Lash Group Oncology franchise with J-code support, FRM coordination, and medical-benefit copay infrastructure.
• EVERSANA. EVERSANA Oncology combines hub, specialty pharmacy (via EVERSANA DIRECT), and commercialization. Strong fit for integrated buy-and-bill plus oral oncolytic launches.
• ConnectiveRx. Buy-and-bill segment is roughly 46 percent of revenue; deep reimbursement and copay experience with a strong medical-benefit copay program.
• AssistRx. Technology-forward hub with eBV and ePA automation. Historically more concentrated in autoimmune and specialty biologics; solid oncology coverage for launches prioritizing digital enrollment.
• CareMetx. Smaller than the top three but growing oncology footprint; competes on configurable platform and mid-market pricing.
• UBC (United Biosource). REMS-certified patient services with deep clinical trial heritage; often selected for REMS-bearing oncology products.

Oncology hub cost ranges: focused single-indication programs (1 to 3K patients) run $3M to $6M annually across 25 to 60 FTEs; broad tumor portfolios (3 to 15K patients) run $6M to $15M across 60 to 150 FTEs; blockbuster checkpoint programs (15K-plus patients) run $15M to $30M-plus across 150 to 400 FTEs. Oncology runs 1.5x to 2x autoimmune costs due to clinical complexity and FRM coordination. Full pricing methodology in Hub Services Buyer’s Guide.

---

Specialty Pharmacies

Oncology specialty pharmacy is split between dedicated oncology SPs and the PBM-owned oncology units. Channel design depends on whether the product is oral, infused, or REMS-bearing.

Dedicated oncology specialty pharmacies

• Onco360. The largest independent oncology-dedicated SP, part of BrightSpring. Deep oncology clinical pharmacist team, oral oncolytic adherence programs, and broad payer network coverage. Frequent LDD partner for oral oncolytic launches.
• Biologics by McKesson. Oncology-dedicated SP within McKesson’s specialty business; pairs natively with McKesson Specialty distribution for integrated oral and infused programs.
• Avella Specialty Pharmacy. Oncology and rare disease focus; acquired by OptionCare Health ecosystem dynamics in flux.

PBM-owned oncology specialty pharmacies

• Accredo. Part of Evernorth/Cigna. Runs 15 Therapeutic Resource Centers including a dedicated oncology TRC. Strong clinical infrastructure, broad payer network, and expanding white-bagging volume for Cigna/ESI oncology mandates.
• CVS Specialty Pharmacy. CVS Health’s specialty unit with oncology focus. Claims the most gene therapy LDD launches of any SP. Aetna integration drives white-bagging volume.
• OptumRx Specialty Pharmacy. UnitedHealth Group’s SP. UnitedHealthcare is the most aggressive payer on white-bagging mandates, so Optum Specialty carries significant mandated oncology volume.
• Walgreens Specialty Pharmacy. Retail-footprint SP with oncology capability, often selected for indications requiring patient pickup or pharmacist consultation.

Limited distribution network design

A typical oral oncolytic LDD network is 3 to 10 pharmacies structured to balance access and control. A common template:

• 1 to 2 dedicated oncology SPs for clinical depth (Onco360, Biologics by McKesson)
• 2 to 3 PBM-owned SPs to cover commercial and Medicare networks (Accredo, CVS Specialty, Optum Specialty)
• 1 to 2 specialty/retail hybrids for broader patient access (Walgreens Specialty)
• Optional: 1 health-system SP partner for 340B patient access

Dispensing fees typically run $10 to $30 per fill; data fees for 867/852 EDI and patient-level reporting run $50K to $250K per SP per year.

See Big 3 PBM Specialty Pharmacies and Top Specialty Pharmacies for Pharma Manufacturers for comparative analysis.

Infusion networks for IV products

White-bagging and site-of-care steering have made the infusion site a strategic variable rather than a default.

• Option Care Health. Largest US home and alternate-site infusion network. Critical partner for maintenance-dose IV oncology moving out of HOPD. Public NASDAQ-listed.
• Naven Health. Ambulatory infusion center network. Growing as PBMs steer infusion from HOPD to lower-cost settings.
• WeInfuse. Infusion center management software platform used across independent infusion centers.

For a buyer-side breakdown of the major home and alternate-site options, see Home Infusion Platforms: CVS Coram vs Option Care Health vs Naven Health.

---

Field Reimbursement and Buy-and-Bill Support

Field reimbursement managers are the single most differentiated cost in an oncology launch versus a rare disease launch. They cannot be outsourced to the hub for complex cases. FRMs cover J-code and coding guidance (especially during the miscellaneous J-code window), payer coverage and payment policy education, complex appeals support, peer-to-peer coordination, site-of-care denial escalation, 340B education for health system customers, white-bagging workflow education, and practice-level economic education (ASP, markup, GPO contracts).

Two provider models dominate. Direct hire: in-house FRM team of 10 to 30 people at $150K to $200K fully loaded. Contract FRM: outsourced through Inizio Engage, Syneos Health Commercial Solutions, Lash Group (Cencora), or Publicis Health at $250K to $350K per head fully loaded but faster to deploy and carrying oncology-trained talent. Most launches use a hybrid model: direct hires for senior leadership and high-complexity markets, contract for rapid scaling.

FRM deployment timing: manager by T-12 to T-15 months, first cohort by T-6, full team in field by T-3. Post-launch, a typical oncology FRM team covers 50 to 300 oncology practices and 20 to 60 health system accounts.

---

Patient Services and Financial Navigation

Oncology patient out-of-pocket exposure is uniquely severe because medical-benefit coinsurance (typically 20 percent) applies to every infusion. A $12,000-per-dose checkpoint inhibitor administered every 3 weeks creates $2,400 per visit in patient responsibility; annual exposure pre-assistance can exceed $30,000 before out-of-pocket max.

Financial navigation must cover: manufacturer-funded commercial copay programs (medical-benefit copay structured as reimbursement after treatment or direct-to-provider payment, not POS adjudication); independent copay foundations for Medicare patients legally excluded from manufacturer copay (HealthWell, PAF, The Assistance Fund, PAN Foundation, Good Days); PAP for uninsured and underinsured; accumulator and maximizer mitigation (roughly 39 percent of commercial lives are in plans using these); and structured financial toxicity screening.

Dedicated vendors: Mandolin for provider-side medical-benefit access automation; TailorMed for provider-side financial navigation deployed at practices and health systems.

Patient advocacy partnerships are budget items, not vendor relationships: typically $250K to $1M per partnership with tumor-specific foundations (ACS, LLS, Susan G. Komen, Prostate Cancer Foundation, Lung Cancer Research Foundation, PanCAN, MMRF).

---

Real-World Evidence and Data Analytics

RWE is more central to oncology launches than to any other therapy area because label expansion, HEOR publications, biomarker-stratified analyses, and outcomes-based contracting all require patient-level oncology data.

Oncology-specific RWE vendors:

• Flatiron Health (Roche). Industry-standard oncology EHR-derived dataset covering 3 million-plus US oncology patients from 280-plus community oncology sites. Used for regulatory submissions, HEOR, label expansion, and comparative effectiveness. Multi-year enterprise agreements typically run $3M to $10M-plus per year.
• ConcertAI. Competing oncology RWE platform with EHR-derived and genomic data. Strong in community oncology and biomarker-stratified research. Similar pricing, often used as Flatiron complement or alternative.
• Tempus (NASDAQ: TEM). Combined genomic and clinical data; strong in biomarker-driven oncology and companion diagnostic research.
• COTA Healthcare. Oncology RWD with proprietary tumor classification (CNA); focused on comparative effectiveness.

General healthcare data vendors: IQVIA (claims, prescribing, analytics for field alignment and payer analytics), Komodo Health (longitudinal claims for patient journey analytics), Clarivate (scientific and regulatory intelligence), Definitive Healthcare (provider and facility data).

Annual data subscription ranges (estimates): claims datasets $500K to $3M; oncology EHR $2M to $10M-plus; genomic $1M to $5M per study; 867/852 SP dispense data $50K to $250K per SP.

See Data Analytics Platforms for Pharma for broader platform coverage.

---

Key Opinion Leaders and Medical Affairs

Oncology is the most KOL-dependent therapy area. A launch-ready oncology medical affairs function includes 15 to 40 US KOLs mapped to the lead indication (plus extended KOLs for label expansion), a 15 to 50-person MSL team for broad tumor launches, advisory board cadence of 2 to 4 per year, congress presence (ASCO, ASH, AACR, ESMO, SABCS), a publication plan with named authors, and HEOR and payer-facing dossiers.

Vendors: Trinity Life Sciences for commercial strategy and KOL mapping; Precision AQ for market access, HEOR, and value communications; Lumanity for medical affairs and value communications; Red Nucleus for medical education; Open Health for specialist market access and medcomms; Indegene for scaled MSL enablement and HCP engagement technology. Veeva Systems provides Vault MedComms, Vault CRM for MSL, and Veeva Link for KOL intelligence; near-ubiquitous in oncology medical affairs.

Commercial teams also facing the forced CRM migration should use Veeva Vault CRM vs Salesforce Life Sciences Cloud as the buyer-side platform comparison.

---

Healthcare Advertising and DTC

DTC advertising applies to broad tumor indications (lung, breast, colorectal, prostate) and to oral oncolytics with direct patient adherence components. It rarely applies to CAR-T or orphan oncology indications.

Oncology-experienced agencies

• Klick Health. Independent healthcare advertising, strong oncology portfolio.
• Publicis Health. Large network agency, deep oncology experience across Saatchi Wellness, Digitas Health, and Real Chemistry.
• IPG Health (Omnicom Health, Area 23, FCB Health). Large oncology client roster.
• W2O Group / Real Chemistry. Integrated marketing and communications.
• McCann Health.

Launch advertising budget varies wildly by indication. A broad tumor-type launch (non-small cell lung cancer, breast, colorectal) can run $30M to $100M-plus in year-one unbranded plus branded advertising. Narrow or orphan oncology indications are predominantly HCP-directed and run $2M to $15M.

---

Cell and Gene Therapy (CAR-T) Launch Variation

CAR-T and cell therapy launches are structurally different enough to warrant their own mini-playbook. Key differences: no traditional SP (manufacturer ships direct to certified treatment centers after autologous cell manufacturing); apheresis coordination with 3 to 6 week vein-to-vein time; CTC network of 80 to 200 sites each requiring onboarding, safety protocols, and product-specific certification; FDA removed REMS for currently approved BCMA- and CD19-directed autologous CAR-T therapies in 2025, but safety monitoring and long-term follow-up remain launch-critical; list prices $400K to $3.5M creating $1M-plus patient exposure absent assistance; outcomes-based contracting emerging; 15-year post-market registries required.

CAR-T vendor stack: hub from Cencora (Lash Group), EVERSANA, or UBC with validated C&GT infrastructure; SP equivalent is manufacturer direct-to-CTC, though CVS Specialty Pharmacy has the most gene therapy LDD launches of any SP; logistics via Cardinal Health 3PL, World Courier (Cencora), or TrakCel; outcomes tracking through Komodo Health, Flatiron, or bespoke registry vendors. Very few vendors have deep validated CAR-T capability; evaluate readiness carefully and plan for custom infrastructure.

---

Gotchas for First-Time Oncology Launchers

These are the recurring failure modes in oncology launches.

1. 340B dynamics. Hospitals in 340B acquire buy-and-bill drugs at the ceiling price (far below ASP) and bill payers at ASP plus markup. The 340B program was $66.3B in 2023 and determines adoption economics in hospital-heavy channels. Community oncology practices lack 340B eligibility in most cases and face different economics. Your payer strategy and GTN model must handle both.

2. White-bagging mandates. UnitedHealthcare has mandated 100-plus drugs through white-bagging since 2020. CVS/Aetna added 5 drugs in July 2025. 84 percent of hospitals have received at least one white-bagging mandate. 12 states have enacted white-bagging restrictions and 32 have introduced legislation, but ERISA preempts state law for self-funded employer plans (60 to 65 percent of commercial lives). Every launch needs a white-bagging playbook per payer.

3. Product-specific safety infrastructure. Some oncology products carry REMS (for example, PML, pregnancy prevention, embryo-fetal toxicity, or other serious risks). Stand-up can take 12-plus months and may require a REMS vendor (often UBC or an SP with REMS infrastructure) plus prescriber certification, patient registry, and ongoing monitoring. CAR-T plans should reflect FDA’s 2025 removal of REMS for currently approved BCMA- and CD19-directed autologous CAR-T therapies while still budgeting for certified-center onboarding and long-term safety follow-up. See Hub Services Market Analysis.

4. IRA Part B exposure. The Inflation Reduction Act brings Medicare Drug Price Negotiation to Part D drugs starting 2026 and Part B drugs starting 2028. Oncology drugs with both Part B (infused) and Part D (oral) SKUs have dual exposure; selected Part D drugs with Part B presentations may carry the negotiated price into Part B. Trinity, Charles River, and Precision AQ offer IRA-specific modeling.

5. Miscellaneous J-codes at launch. New drugs without a permanent J-code bill under miscellaneous codes (J3490, J3590, J9999) for 12 to 18 months post-approval. Payers handle these inconsistently. Under-resourcing FRM support during this window slows uptake meaningfully.

6. Community vs academic split. Community oncology (USON, OneOncology, American Oncology Network) dispenses most US oncology volume on tight margins. Academic NCCN centers drive KOL influence and label-expansion data. FRM, medical affairs, and advocacy strategies must be dual-channel.

7. Site-of-care steering. Payers push IV oncology out of HOPD (highest cost) into physician office infusion, ambulatory centers, or home infusion. Launch teams need a site-of-care plan with Option Care Health, Naven Health, and WeInfuse-enabled centers as coverage partners.

---

Launch Budget Summary (Mid-Size Oncology Launch, Year 1)

Estimates for an IV biologic oncology launch with 3 to 10K addressable patients in year 2.

Line	Year 1 Spend	Notes
Hub services	$4M to $8M	Medical-benefit capability, FRM coordination
Specialty pharmacy (LDD fees + data)	$500K to $2M	Data and minimum dispensing guarantees
Field reimbursement (10 to 25 FRMs)	$2M to $6M	Hybrid direct / contract
Specialty distributor (GPO fees, 3PL)	$1M to $4M	McKesson, Cencora, Cardinal
REMS vendor	$500K to $2M	If required
Real-world evidence (Flatiron, ConcertAI, Tempus)	$2M to $8M	Multi-year commitments common
Claims and analytics (IQVIA, Komodo)	$500K to $3M	Field alignment, payer analytics
Medical affairs (MSLs, advisory boards, pubs)	$5M to $15M	15 to 50 MSLs
Market access consulting and HEOR	$1M to $3M	Pricing, GTN, dossiers
Patient advocacy partnerships	$500K to $2M	Tumor-specific foundations
Healthcare advertising (if broad indication)	$20M to $100M-plus	Excluded from vendor-stack total

Total vendor stack (excluding advertising): roughly $15M to $50M year-one spend. Adding advertising can easily double this for broad tumor indications. Estimates are ranges based on public deal sizes and industry benchmarks; exact numbers are always negotiated.

For direct contrast, see the analogous Rare Disease Launch Playbook, which typically runs $3M to $15M year-one vendor spend (lower SP and FRM cost, but higher per-patient case management).

---

How to Sequence Vendor Selection

A working sequence for an oncology launch starting at T-18 months: (1) channel strategy and archetype decision (T-18); (2) market access consulting engagement (T-18) with Trinity, Charles River, Precision AQ, or Lumanity; (3) RWE dataset selection (T-15) across Flatiron, ConcertAI, and Tempus (multi-year agreements take 3 to 6 months to negotiate); (4) hub services RFP (T-15 start, T-10 contract), see Hub Services Buyer’s Guide; (5) SP network design and LDD contracting (T-12 to T-8); (6) GPO and specialty distributor contracting (T-12); (7) field reimbursement build (T-12 manager, T-6 team); (8) REMS vendor (T-12 if required); (9) medical affairs build (T-12 to T-6); (10) patient advocacy partnerships (T-9); (11) healthcare advertising agency (T-9 if applicable); (12) launch dry runs (T-3).

---

Caveats

Figures are industry benchmarks and estimates. Exact numbers vary by indication, geography, and negotiated terms. Where a figure is disclosed (Flatiron patient count, white-bagging state counts, 340B program size), it is cited; all other figures should be treated as ranges useful for planning, not contractual inputs.